DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Doi.org Make Money
Keywords
Topics
Questions
Schema
External Links
Analytics And Tracking
Libraries
Hosting Providers
CDN Services

We began analyzing https://link.springer.com/article/10.1007/s12325-012-0044-6, but it redirected us to https://link.springer.com/article/10.1007/s12325-012-0044-6. The analysis below is for the second page.

Title[redir]:
Effects of Thiazolidinediones on Polycystic Ovary Syndrome: a Meta-analysis of Randomized Placebo-Controlled Trials | Advances in Therapy
Description:
Introduction Thiazolidinedione (TZD) is one of the therapy options for polycystic ovary syndrome (PCOS) patients; however, the effectiveness of TZD in the treatment of PCOS remains controversial. The aim of this metaanalysis was to clarify the role that TZDs play in the treatment of PCOS. Methods The authors searched the following databases for any date up to June 2012 for randomized controlled trials on PCOS treatment in which interventions for the experimental and control groups were TZDs and placebo, respectively: Medline, Embase, and the Cochrane library. Results The search strategy identified 173 potential publications, eight of which were included. In the treatment of PCOS, the insulin-lowering effects of TZDs were superior to placebo (95% CI −1.50 to −0.12; P = 0.021), and the lowering of fasting blood glucose was superior to placebo (95% CI −1.06 to −0.05; P = 0.031). There was no difference in reduction of the Ferriman-Gallwey scores or the androgen levels between TZDs and placebo (95% CI −0.57 to 0.10; P = 0.169 and 95% CI −0.64 to 0.09; P = 0.141, respectively). The effects of TZDs on body weight reduction were inferior to placebo (95% CI 0.13 to 0.66; P = 0.003). Significant between-study heterogeneity was detected for several variables assessed. Conclusion This is the first meta-analysis to evaluate the role that TZDs plays in the treatment of PCOS compared with placebo. The currently available data showed that TZDs can effectively reduce insulin and fasting blood glucose levels in patients with PCOS, but TZDs may not effectively reduce the Ferriman-Gallwey score or androgen levels and may increase body weight.

Matching Content Categories {📚}

Health & Fitness
Education
Insurance

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🏙️ Massive Traffic: 50M - 100M visitors per month

Based on our best estimate, this website will receive around 80,479,999 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We see no obvious way the site makes money.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Doi.org might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

article, google, scholar, pubmed, cas, polycystic, syndrome, ovary, women, pcos, treatment, clin, metaanalysis, insulin, thiazolidinediones, trials, tzds, endocrinol, effects, metformin, study, risk, pioglitazone, rosiglitazone, randomized, placebo, metabolic, med, patients, effect, cardiovascular, metab, cancer, clinical, china, privacy, cookies, content, search, access, diabetes, data, publish, therapy, placebocontrolled, controlled, glucose, androgen, hepatic, drug,

Topics {✒️}

month download article/chapter fasting blood glucose randomized placebo-controlled trials randomized placebo-controlled study polycystic ovary syndrome—association placebo-controlled clinical trial australian case-control study equally insulin-resistant women yan-jun wang full article pdf polycystic ovary syndrome privacy choices/manage cookies randomized controlled trials polycystic ovarian syndrome longitudinal cohort study controlled clinical trials prospective randomized study ferriman-gallwey score cardiovascular system preferred reporting items dallas heart study long-term risk china medical university zhao jj article advances contemp clin trials insulin resistance insulin-resistant patients european economic area ferriman-gallwey scores increase body weight elevated glycated hemoglobin lipoprotein subclass patterns local recruitment experience achieving weight loss enhances progesterone biosynthesis porcine theca cells pharmacoepidemiol drug saf dig dis sci luteinizing hormone secretion morin-papunen lc body hair growth external link http biochim biophys acta insulin sensitizers metformin article du conditions privacy policy consensus statement metformin versus metformin clin endocrinol metab

Questions {❓}

PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Effects of Thiazolidinediones on Polycystic Ovary Syndrome: a Meta-analysis of Randomized Placebo-Controlled Trials
         description:Thiazolidinedione (TZD) is one of the therapy options for polycystic ovary syndrome (PCOS) patients; however, the effectiveness of TZD in the treatment of PCOS remains controversial. The aim of this metaanalysis was to clarify the role that TZDs play in the treatment of PCOS. The authors searched the following databases for any date up to June 2012 for randomized controlled trials on PCOS treatment in which interventions for the experimental and control groups were TZDs and placebo, respectively: Medline, Embase, and the Cochrane library. The search strategy identified 173 potential publications, eight of which were included. In the treatment of PCOS, the insulin-lowering effects of TZDs were superior to placebo (95% CI −1.50 to −0.12; P = 0.021), and the lowering of fasting blood glucose was superior to placebo (95% CI −1.06 to −0.05; P = 0.031). There was no difference in reduction of the Ferriman-Gallwey scores or the androgen levels between TZDs and placebo (95% CI −0.57 to 0.10; P = 0.169 and 95% CI −0.64 to 0.09; P = 0.141, respectively). The effects of TZDs on body weight reduction were inferior to placebo (95% CI 0.13 to 0.66; P = 0.003). Significant between-study heterogeneity was detected for several variables assessed. This is the first meta-analysis to evaluate the role that TZDs plays in the treatment of PCOS compared with placebo. The currently available data showed that TZDs can effectively reduce insulin and fasting blood glucose levels in patients with PCOS, but TZDs may not effectively reduce the Ferriman-Gallwey score or androgen levels and may increase body weight.
         datePublished:2012-08-28T00:00:00Z
         dateModified:2012-08-28T00:00:00Z
         pageStart:763
         pageEnd:774
         sameAs:https://doi.org/10.1007/s12325-012-0044-6
         keywords:
            Fasting blood glucose
            Hirsutism
            Insulin resistance
            Polycystic ovary syndrome
            Thiazolidinediones
            Internal Medicine
            Oncology
            Cardiology
            Rheumatology
            Endocrinology
            Pharmacology/Toxicology
         image:
         isPartOf:
            name:Advances in Therapy
            issn:
               1865-8652
               0741-238X
            volumeNumber:29
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Healthcare Communications
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Qiang Du
               affiliation:
                     name:Shengjing Hospital of China Medical University
                     address:
                        name:Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Sheng Yang
               affiliation:
                     name:Shengjing Hospital of China Medical University
                     address:
                        name:Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yan-Jun Wang
               affiliation:
                     name:Shengjing Hospital of China Medical University
                     address:
                        name:Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Bo Wu
               affiliation:
                     name:Shengjing Hospital of China Medical University
                     address:
                        name:Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yue-Yang Zhao
               affiliation:
                     name:Shengjing Hospital of China Medical University
                     address:
                        name:Library, Shengjing Hospital of China Medical University, Shenyang, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Bin Fan
               affiliation:
                     name:Shengjing Hospital of China Medical University
                     address:
                        name:Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, China
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Effects of Thiazolidinediones on Polycystic Ovary Syndrome: a Meta-analysis of Randomized Placebo-Controlled Trials
      description:Thiazolidinedione (TZD) is one of the therapy options for polycystic ovary syndrome (PCOS) patients; however, the effectiveness of TZD in the treatment of PCOS remains controversial. The aim of this metaanalysis was to clarify the role that TZDs play in the treatment of PCOS. The authors searched the following databases for any date up to June 2012 for randomized controlled trials on PCOS treatment in which interventions for the experimental and control groups were TZDs and placebo, respectively: Medline, Embase, and the Cochrane library. The search strategy identified 173 potential publications, eight of which were included. In the treatment of PCOS, the insulin-lowering effects of TZDs were superior to placebo (95% CI −1.50 to −0.12; P = 0.021), and the lowering of fasting blood glucose was superior to placebo (95% CI −1.06 to −0.05; P = 0.031). There was no difference in reduction of the Ferriman-Gallwey scores or the androgen levels between TZDs and placebo (95% CI −0.57 to 0.10; P = 0.169 and 95% CI −0.64 to 0.09; P = 0.141, respectively). The effects of TZDs on body weight reduction were inferior to placebo (95% CI 0.13 to 0.66; P = 0.003). Significant between-study heterogeneity was detected for several variables assessed. This is the first meta-analysis to evaluate the role that TZDs plays in the treatment of PCOS compared with placebo. The currently available data showed that TZDs can effectively reduce insulin and fasting blood glucose levels in patients with PCOS, but TZDs may not effectively reduce the Ferriman-Gallwey score or androgen levels and may increase body weight.
      datePublished:2012-08-28T00:00:00Z
      dateModified:2012-08-28T00:00:00Z
      pageStart:763
      pageEnd:774
      sameAs:https://doi.org/10.1007/s12325-012-0044-6
      keywords:
         Fasting blood glucose
         Hirsutism
         Insulin resistance
         Polycystic ovary syndrome
         Thiazolidinediones
         Internal Medicine
         Oncology
         Cardiology
         Rheumatology
         Endocrinology
         Pharmacology/Toxicology
      image:
      isPartOf:
         name:Advances in Therapy
         issn:
            1865-8652
            0741-238X
         volumeNumber:29
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Healthcare Communications
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Qiang Du
            affiliation:
                  name:Shengjing Hospital of China Medical University
                  address:
                     name:Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Sheng Yang
            affiliation:
                  name:Shengjing Hospital of China Medical University
                  address:
                     name:Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yan-Jun Wang
            affiliation:
                  name:Shengjing Hospital of China Medical University
                  address:
                     name:Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Bo Wu
            affiliation:
                  name:Shengjing Hospital of China Medical University
                  address:
                     name:Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yue-Yang Zhao
            affiliation:
                  name:Shengjing Hospital of China Medical University
                  address:
                     name:Library, Shengjing Hospital of China Medical University, Shenyang, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Bin Fan
            affiliation:
                  name:Shengjing Hospital of China Medical University
                  address:
                     name:Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, China
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Advances in Therapy
      issn:
         1865-8652
         0741-238X
      volumeNumber:29
Organization:
      name:Springer Healthcare Communications
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Shengjing Hospital of China Medical University
      address:
         name:Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China
         type:PostalAddress
      name:Shengjing Hospital of China Medical University
      address:
         name:Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China
         type:PostalAddress
      name:Shengjing Hospital of China Medical University
      address:
         name:Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China
         type:PostalAddress
      name:Shengjing Hospital of China Medical University
      address:
         name:Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China
         type:PostalAddress
      name:Shengjing Hospital of China Medical University
      address:
         name:Library, Shengjing Hospital of China Medical University, Shenyang, China
         type:PostalAddress
      name:Shengjing Hospital of China Medical University
      address:
         name:Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Qiang Du
      affiliation:
            name:Shengjing Hospital of China Medical University
            address:
               name:Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Sheng Yang
      affiliation:
            name:Shengjing Hospital of China Medical University
            address:
               name:Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China
               type:PostalAddress
            type:Organization
      name:Yan-Jun Wang
      affiliation:
            name:Shengjing Hospital of China Medical University
            address:
               name:Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China
               type:PostalAddress
            type:Organization
      name:Bo Wu
      affiliation:
            name:Shengjing Hospital of China Medical University
            address:
               name:Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China
               type:PostalAddress
            type:Organization
      name:Yue-Yang Zhao
      affiliation:
            name:Shengjing Hospital of China Medical University
            address:
               name:Library, Shengjing Hospital of China Medical University, Shenyang, China
               type:PostalAddress
            type:Organization
      name:Bin Fan
      affiliation:
            name:Shengjing Hospital of China Medical University
            address:
               name:Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, China
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China
      name:Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China
      name:Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China
      name:Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China
      name:Library, Shengjing Hospital of China Medical University, Shenyang, China
      name:Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, China
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(193)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

Emails and Hosting {✉️}

Mail Servers:

mx.zoho.eu
mx2.zoho.eu
mx3.zoho.eu

Name Servers:

josh.ns.cloudflare.com
zita.ns.cloudflare.com

CDN Services {📦}

Crossref

4.37s.